A Study of SKB107 in Advanced Solid Tumors With Bone Metastases

Exclusion Criteria15

• The washout period before the first administration of the study drug was insufficient.
• Previous received similar radionuclide internal irradiation treatment.
• Previous received or planned to receive during the study period semi-body external radiotherapy targeting bone metastases.
• Known "super bone imaging".
• Known spinal cord compression, or clinical imaging manifestations suggesting impending spinal cord compression.
• Any cardiovascular or cerebrovascular diseases or cardiovascular risk factors that may affect the treatment of the study drug.
• Poorly controlled diabetes and hypertension.
• Had other malignant tumors within 3 years before the first administration.
• Subjects with severe and/or uncontrolled concomitant diseases.
• Active hepatitis B or active hepatitis C.
• Human immunodeficiency virus (HIV) test positive or having a history of acquired immune deficiency syndrome (AIDS); known active syphilis infection.
• Subjects with a history of radionuclide/radioactive drug allergy, or allergic to any component of the study formulation.
• During the screening process before the first administration, the condition deteriorated rapidly, such as significant changes in the investigator's assessment of physical condition, etc.
• Subjects participating in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an intervention study.
• Any unstable disease or clinical condition, or any condition that may endanger the safety of the subject or affect the subject's compliance, or any other conditions that the investigator deems inappropriate for participation in this study.